



The difference between  
feeling better and getting better.®

Discover if Adequan® Canine is the right choice for your canine patients.

**Feature #1:**

Only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for the treatment of OA-diagnosed synovial joints in dogs.<sup>1</sup>

**Benefit #1:**

Efficacy studies have shown it inhibits the loss of key joint components, including: proteoglycan, collagen and hyaluronic acid to help promote a rich matrix for joint movement stability. In vitro studies confirmed it inhibits catabolic enzymes which can destroy these molecules.<sup>2</sup>

**Feature #2:**

Delivers a proven and reliable difference to help slow the progression of canine OA.

**Benefit #2:**

Adequan Canine (polysulfated glycosaminoglycan), for more than 20 years has effectively helped to improve mobility in dogs with OA. It's the only prescription reaching the synovial joint within 2 hours to proactively help treat the disease and reduce joint inflammation.<sup>2</sup>

The specific mechanism of action of Adequan® in canine joints is not known.<sup>1</sup>

**Feature #3:**

Early OA intervention with Adequan Canine can help more dogs enjoy more everyday adventures.

**Benefit #3:**

Estimated 1 in 5 dogs over 1-year old may be affected by OA.<sup>3</sup> Yet, +50% of OA cases are diagnosed in dogs 8-13 years old.<sup>4</sup> Many cases go undiagnosed or diagnosed late in the disease process after significant joint damage.<sup>5</sup>

**Early diagnosis +  
early treatment =  
greater success with OA.**

Adequan® Canine, brand of polysulfated glycosaminoglycan (PSGAG)

**INDICATIONS** Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

**IMPORTANT SAFETY INFORMATION** Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. *For additional safety information, please see Full Prescribing Information at [adequancanine.com](http://adequancanine.com).*

**References:**

1. Adequan® Canine Package Insert, Rev. 1/19
2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997.
3. Clinician's Brief, Aug. 2013, Canine OA, DA Canapp, DVM, CCRT, CVA, DACVSMR.
4. Mele, E. Epidemiology of Osteoarthritis. Veterinary Focus 17, 4-10 (2007).
5. 2016 NAVC Proceedings, Osteoarthritis in Dogs & Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR.

Adequan is a registered trademark and the Dog Head design is a trademark of American Regent, Inc.

© 2020, American Regent, Inc. PP-AC-US-0303 8/2020

**sound  
byte**

**For more information on this product...**

[www.adequancanine.com](http://www.adequancanine.com) • [cs@americanregent.com](mailto:cs@americanregent.com)

ARAH Team Phone: 800-458-0163

**Fax:** 866-597-1991

265 Broadhollow Road, Melville, NY 11747

# What does Adequan® Canine offer?

## Product Features

|                                                                                                                                                          | Adequan® Canine* | Oral Joint Supplements** | NSAIDs |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------|--------|
| Only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for dogs <sup>1</sup>                                                                    | ✓                | ✗                        | ✗      |
| FDA-reviewed studies with proven efficacy results for treating the OA disease process in dogs <sup>1</sup>                                               | ✓                | ✗                        | ✗      |
| Approved canine formula – polysulfated with a low molecular weight, allowing for diffusion into the joint and deposition into the cartilage <sup>1</sup> | ✓                | ✗                        | ✗      |
| Shown to inhibit catabolic enzymes and promote anabolic activity in the joint <sup>1</sup>                                                               | ✓                | ✗                        | ✗      |
| Shown to reduce inflammation                                                                                                                             | ✓                | ✗                        | ✓      |
| Veterinary prescription only                                                                                                                             | ✓                | ✗                        | ✓      |
| Product quality assurance, consistency and manufacturing with FDA-label requirements                                                                     | ✓                | ✗                        | ✓      |
| Long-standing safety profile and post-approval monitoring and reporting of adverse events with FDA                                                       | ✓                | ✗                        | ✓      |

\*The specific mechanism of action of Adequan® in canine joints is not known. \*\*Not FDA-approved NSAIDs – Nonsteroidal anti-inflammatory drugs. All products have the potential for adverse events that should be considered in overall management of any disease.

1. Adequan® Canine Package Insert, Rev. 1/19.

## Rethink OA / Think DMOAD

Owners want the best for their dogs and in a recent dog owner survey it confirmed **92% showed an interest** when asked about a DMOAD treatment for their OA-diagnosed dog with **56% very interested**.<sup>6</sup> Of those with dogs in the **early stage**, **52% were interested** and of those at a **moderate stage**, **60% were interested** in using Adequan Canine. Unfortunately, the study also indicated **64% had never heard of the DMOAD** term for treating their OA diagnosed dog. Remind owners Adequan Canine (polysulfated glycosaminoglycan) is approved to help treat the disease and not just the signs of OA. As the only DMOAD for OA treatment it empowers a dog diagnosed with OA the ability to help them manage their disease and slow the progression of osteoarthritis to enjoy everyday adventures throughout their life.

6. DMOAD Pet Owner Research, Kaufman Research, Inc. October 2019. (n = 385 / Dog owners with OA diagnosed dogs, +/- 4.9% at 95% level of confidence.)



**Adequan Canine™**  
polysulfated glycosaminoglycan

## sound byte

CHECK-OFF &  
ECHO NOTES

### Start an Effective Team to Pet Owner Conversation

If engaging in an initial discussion, state the issue:

Ms. Jones, watching your dog walk across the room, I think Rover may be showing signs of osteoarthritis. Can I ask, is he becoming less interested in walking or playing? Does he hesitate going up stairs? OA is a disease that will only progress and get worse. If we can identify and diagnose earlier, we'll have a better chance of helping to manage with greater success.

### STATE THE SOLUTION

Let's ask your veterinarian to check Rover's joint movement today and a product you might want to ask about is Adequan Canine. It is the only approved disease-modifying OA drug and has shown it may help slow the progression of canine osteoarthritis, if that is what we discover. It also works to reduce the inflammation associated with OA and can help to inhibit the damaging enzymes associated with the disease progression.

### MAKE YOUR RECOMMENDATION

Ms. Jones let's be sure to ask the veterinarian if Adequan® Canine is a good fit for Rover. Keep in mind it is a commitment on your part, a 4-week treatment of 2 injections per week, but it is a good solution to consider helping you manage canine osteoarthritis disease.

### CUSTOMER'S DECISION

...so you can decide whether Adequan® Canine is a solution you'll recommend for your patients presenting signs of osteoarthritis or degenerative joint disease.